Our primary ambition is to find innovative projects and products that will advance neuroscience and develop novel and innovative treatments for patients. By combining our internal R&D capabilities with external alliances, we significantly broaden the opportunities to achieve our end goal. These include:
- Discovery technology platforms
- Enabling technologies, such as biomarkers and imaging
- Digital platforms, such as wearables
- Discovery projects
- Pre-clinical projects
- Early and mid-stage developments projects
- Regional and global commercialised products
Successful partnerships, from early-stage science to commercialisation, have been one of the main drivers in establishing Lundbeck’s current position in brain science. We actively seek access to external innovation, particularly where we see best-in-class opportunities to develop transformative medicines, and where we can leverage our own global drug development and commercial expertise to bring new medicines to patients.
Our partnerships are equally valued, whether small or large, which allows us to fine-tune each partnership according to specific needs and circumstances. Across our therapeutic, technological and research areas, we seek:
- Open innovation
- Academic collaborations
- Equity investments
Current Partnerships & Alliance Management
The treatments we have launched over the last 10 years demonstrate Lundbeck’s ability and commitment to establishing exceptional partnerships. Once we’ve entered into a partnership, our Strategic Alliance Management Team takes the lead on laying the foundation for a well-functioning relationship.
Local and Global Deals
Neurological and psychiatric diseases are global issues. Therefore, we seek to leverage our innovative culture, expertise and reputation to build on our global presence by bringing innovative therapies to each and every market.